Regorafenib (STIVARGA) Is Guideline-recommended as a 3rd-Line Option in mCRC in Appropriate Patients
The efficacy of STIVARGA in 3rd-line mCRC has been proven in two phase 3 trials
- The repeated use of chemotherapy (oral or intravenous) beyond the 2nd line in mCRC has not been clinically shown to have a survival benefit in any large, randomized study
- Re-treatment with an anti-EGFR agent is not guideline-recommended